Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML

NCT04501120 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

682

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory Acute Myeloid Leukaemia
Myeloid Malignancy

Interventions

DRUG: Lisaftoclax (APG-2575)
DRUG: Reduced-dose HHT
DRUG: standard-dose HHT
DRUG: Azacitidine
DRUG: Lisaftoclax (APG-2575)
DRUG: olverembatinib

Sponsor

Ascentage Pharma Group Inc.

Collaborators

[object Object]